Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14823828 | 0.93 | CYP3A4 (0.36) | CYP3A4LIPGMMP2MMP9PSIP1 | |
| SCHEMBL14810084 | 0.92 | CYP3A4 (0.36) | CYP3A4LIPGMMP2MMP9PSIP1 | |
| SCHEMBL14809798 | 0.90 | CYP3A4 (0.36) | CYP3A4LIPGMMP2MMP9PSIP1 | |
| SCHEMBL14809136 | 0.89 | MAPT (0.37) | CYP3A4PPARGPPARALIPGMMP2 | |
| SCHEMBL14810628 | 0.88 | MEN1 (0.34) | CYP3A4KMT2A | |
| SCHEMBL14810111 | 0.87 | MAPT (0.39) | CYP3A4PPARGPPARALIPGKDM4E | |
| SCHEMBL14809836 | 0.86 | MAPT (0.36) | CYP3A4KMT2AALDH1A1MAPT | |
| SCHEMBL16252239 | 0.84 | CYP3A4 (0.34) | CYP3A4LIPGPSIP1 | |
| SCHEMBL16252244 | 0.84 | CYP3A4 (0.36) | CYP3A4KDM4EALDH1A1MAPT | |
| SCHEMBL14810135 | 0.84 | CYP3A4 (0.34) | CYP3A4LIPGPSIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | DHPS, PRNP, TYMP | CYP3A4 573/4885PPARG 1365/4885PPARA 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.